Clearside Biomedical

Clearside Biomedical Cash Conversion

Delisted

The Cash Conversion Rate (OCF/Net Income) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 71.90 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 55.83 % — a change of 28.79% (higher).

Cash Conversion

71.90 %

YoY

28.79%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Clearside Biomedical is 2024 71.90 % . Cash Conversion Rate (OCF/Net Income) of Clearside Biomedical was 2023 55.83 % . It decreases by 28.79% higher compared to the previous year.

The Clearside Biomedical Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2017
86.61 USD
Jan 1, 2018
95.63 USD
Jan 1, 2019
87.98 USD
Jan 1, 2020
72.05 USD
Jan 1, 2021
-2,823.68 USD
Jan 1, 2022
40.58 USD
Jan 1, 2023
55.83 USD
Jan 1, 2024
71.90 USD
The Clearside Biomedical Cash Conversion history
YEARCash ConversionYoY
71.90 %+28.79%
55.83 %+37.58%
40.58 %-101.44%
-2,823.68 %-4,019.15%
72.05 %-18.10%
87.98 %-8.00%
95.63 %+10.42%
86.61 %-1.31%
87.75 %+11.36%
78.80 %-11.96%
89.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Cash Conversion Rate (OCF/Net Income) of Clearside Biomedical is 71.90 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Clearside Biomedical changed from 55.83 % to 71.90 %, representing a 28.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clearside Biomedical

All Key Metrics — Clearside Biomedical